Status:
UNKNOWN
Multiplex Analysis of Circulating Tumor DNA
Lead Sponsor:
Peking University People's Hospital
Conditions:
Carcinoma
Non-small-cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Lung cancer is the leading cause of cancer-related death in China. This study will explore the applications of multiplex analysis of circulating tumor DNA biomarkers for diagnosis and surveillance of ...
Detailed Description
Non-small cell lung cancer (NSCLC) constitutes about 85% of all newly diagnosed cases of lung cancer and continues to be the leading cause of cancer-related deaths worldwide.Early diagnosis and monito...
Eligibility Criteria
Inclusion
- Sign informed consent and consent to participate in this study;
- Found small nodules in pulmonary by CT and prepare for surgery;
Exclusion
- Malignant tumor history within the past 5 years;
- Receiving chemotherapy, radiotherapy or targeted therapy before surgery;
- No matching tissue or blood samplesUnqualified blood samples
- Lesion is pure ground glass opacity.
Key Trial Info
Start Date :
April 11 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03301961
Start Date
April 11 2019
End Date
June 1 2022
Last Update
February 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044